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Transforming growth factor-b1 (TGF-b1) plays a fundamental
role in the progression of renal diseases. Accumulating
evidence has suggested that eicosanoids derived from
cyclooxygenase-2 (COX-2) participate in a number of
pathological processes in immune-mediated renal diseases.
Mesangial cells (MC) play a major role in physiological and
pathophysiological renal processes. MC express receptors for
TGF-b1, and COX-2 expression can be induced in MC.
However, to date, there are no published data on the
possible role of TGF-b1 in COX-2 expression in human
mesangial cells (HMC). We designed studies to determine (1)
whether TGF-b1 stimulates COX-2 expression in primary
HMC, (2) whether mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K) cascades are
involved in TGF-b1-induced COX-2 expression, and (3)
whether prostaglandin (PG)E2 synthesis is affected by
TGF-b1 and MAP kinases and PI3K activation. Studies were
performed in primary cultures of HMC and in an
immortalized line of HMC. TGF-b1 induces COX-2 promoter
activity and COX-2 mRNA and protein expression in HMC.
COX-2 induction is accompanied by increased PGE2 synthesis.
Extracellular signal-regulated kinase (ERK)1/2, p38 MAPK, and
PI3K pathway inhibition blunted TGF-b1-induced COX-2
overexpression. We demonstrate that TGF-b1 regulates
COX-2 expression in HMC through the activation of ERK1/2,
p38 MAPK, and PI3K. These results can help to elucidate
the molecular mechanisms underlying the regulation of
COX-2 and open up specific strategies for the treatment
of glomerular disease.
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Glomerular mesangial cells (MC) play a key role in
glomerular sclerosis and in the maintenance of immune
functions of the glomeruli.1 MC damage may lead to a
serious deterioration of glomerular functions. Accumula-
ting evidence has suggested that specific eicosanoids
participate in a number of pathological processes leading
to end-stage renal disease.2 Cyclooxygenase (COX), also
known as prostaglandin (PG)G/H synthase, is a membrane-
bound, bifunctional enzyme that catalyzes the conversion
of arachidonic acid to PGG2 by its COX activity and of PGG2
to PGH2 by peroxidase activity. It is the rate-limiting step in
the biosynthesis of biologically active and physiologi-
cally important PGs.3 Two isoforms of COX have been
identified, COX-1 and COX-2.4 COX-1 is constitutively
expressed in most tissues. In contrast, COX-2 operates as an
inducible enzyme with low or undetectable levels in most
tissues.5 COX-2 expression is induced by cytokines, tumour
promoters, and growth factors (reviewed by Williams and
DuBois4 and Kramer et al.6). Increased renal expression of
COX-2 has been reported in nephropathies such as renal
failure,6 diabetic nephropathy,7 and systemic lupus erythe-
matosus.8 However, some of the pathways involved in the
mesangial synthesis of PG via COX-2 as well the biologic
consequences of glomerular PG synthesis remain poorly
understood.
COX-2 expression is regulated by multiple signalling
pathways and its regulation is cell type and stimulus
dependent.9 Among the mechanisms involved in the regula-
tion of COX-2 expression, the activation of small Guanine
triphosphatase ras10,11 and several mitogen-activated protein
kinases (MAPK)12 seems to play a major role.
Extensive studies have demonstrated that transforming
growth factor-b (TGF-b) plays an important role in the
progression of renal diseases.13 TGF-b1 has been linked
mainly to fibrogenesis in experimental models of glomer-
ulonephritis and diabetic nephropathy.14 Interestingly, one of
the remarkable effects of TGF-b1 is the induction of COX-2
expression.15–17 However, there are no data on the possible
effect of TGF-b on COX-2 expression in MC. Based upon the
observations that COX-2 is expressed in kidney diseases and
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in MC6 and that TGF-b1 is overexpressed in renal fibrosis
and in stimulated MC,18 we hypothesized that TGF-b1 may
play a role in the regulation of COX-2 expression in human
mesangial cells (HMC). Thus, a major purpose of this study
was to assess whether TGF-b1 stimulates COX-2 expression
in primary cultured HMC.
In the present study, we demonstrate for the first time that
exogenous TGF-b1 induces COX-2 promoter activity and
COX-2 mRNA and protein expression in HMC. In addition,
we demonstrate that TGF-b1 regulates COX-2 expression in
HMC through several signalling routes including activa-
tion of p38, extracellular signal-regulated kinase (ERK)1/2,
and Akt.
RESULTS
TGF-b1 induces COX-2 expression in HMC
The first aim of this study was to determine whether TGF-b1
induced COX-2 expression in primary HMC. For this
purpose, proteins from cells extracts treated with TGF-b1
were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and analyzed by Western blotting using an
anti-COX-2 antibody. Subconfluent serum-starved HMC
expressed relatively low levels of COX-2 protein (Figure
1a). Stimulation of these cells with TGF-b1 (1 ng/ml) induced
a marked increase in COX-2 protein, which was evident
within 4 h after agonist treatment, reached a maximum at
24 h, and the increase remained detectable for up to 48 h
(Figure 1a). COX-2 protein levels were also measured in cells
treated with increasing amounts of TGF-b1 (0.1, 1, and
10 ng/ml) for 24 h. A concentration-dependent increase in
COX-2 expression was observed (Figure 1b). COX-1 was
constitutively expressed and did not change after TGF-b1
treatment (Figure 1a and b).
We next assessed whether the TGF-b1-induced increase in
COX-2 expression has a functional consequence such as an
increase in prostanoids production. PGE2 is a major product
of COX-initiated arachidonic acid metabolism in MC.19 We
found that TGF-b1 at 1 ng/ml induced PGE2 production in a
time-dependent manner. TGF-b1-induced PGE2 generation
was increased after 4 h, and the highest PGE2 concentration
was achieved at 24–48 h of stimulation (Figure 2a). The time
course of TGF-b1-induced increase in PGE2 production was
similar to that for COX-2 expression. PGE2 concentration
was corrected by the protein content in each culture plate.
These data suggest that the increase in COX-2 expression is
functional. To verify whether the increase in PGE2 produc-
tion induced by TGF-b1 is based on COX-2 increase, HMC
were pretreated with the specific inhibitor of COX-2 activity
NS-398 (10 mM). This substance blocked TGF-b1-induced
PGE2 production but not TGF-b1-induced COX-2 expres-
sion (Figure 2b). These results demonstrate that the increase
in PGE2 production induced by TGF-b1 is mediated by
upregulation of COX-2 expression.
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Figure 1 | Time- and dose-dependent induction of COX-2 by
TGF-b1. (a) HMC were serum-starved for 24 h and treated with
TGF-b1 (1 ng/ml) for the indicated time points. Total protein lysates
were analyzed by Western blotting using anti COX-1 and COX-2
antibodies. Equal amounts of protein were loaded in each lane, which
was verified by blotting with anti-a-tubulin. (b) Serum-starved HMC
were treated with increasing amounts of TGF-b1 (0.1–10 ng/ml) for
24 h. Cells were lysed and COX-1 and COX-2 expression was analyzed
by Western blotting. Results are expressed as the mean7s.e.m. of,
at least, two independent experiments.
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Figure 2 | TGF-b1 induces COX-2-dependent PGE2 production.
(a) HMC were serum-starved (24 h) before stimulation with TGF-b1
(1 ng/ml) and PGE2 ELISA analysis was performed in the culture
medium. PGE2 levels were corrected by protein amount present in
each plate. (b) Serum-starved HMC were untreated or treated with
the specific COX-2 inhibitor NS-398 (10 mM) 1 h before incubation with
TGF-b1 (1 ng/ml) for 24 h. Protein extracts were analyzed by Western
blotting for COX-2 expression. The culture medium was collected to
measure PGE2 by ELISA. (c) Serum-starved HMC were untreated or
treated with the sTbRII (500 ng/ml) and/or with TGF-b1 (1 ng/ml) for
24 h. Protein extracts were analyzed by Western blotting for COX-2
expression. The culture medium was collected to measure PGE2 by
ELISA. Results are expressed as the mean7s.e.m. of, at least, two
independent experiments.
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To determine the specificity of TGF-b1-dependent induc-
tion of COX-2 and PGE2, HMC were pretreated with the
soluble TGF-b receptor II (sTbRII) (500 ng/ml) before
treatment with TGF-b1 (1 ng/ml) for 24 h. Soluble TGF-b1
receptor II inhibited both the TGF-b1-induced COX-2
expression and the increased PGE2 release (Figure 2c).
TGF-b1-dependent COX-2 expression involves transcriptional
mechanisms
COX-2 expression is highly regulated by both transcriptional
and post-transcriptional mechanisms, depending on its
activator and the cell type.20,21 Thus, our next purpose was
to determine whether TGF-b1 increases COX-2 gene
expression in HMC. For this purpose, total RNA was isolated
from cells treated with TGF-b1 (1 ng/ml) for various time
points (1–48 h). The levels of COX-2 mRNA were measured
by reverse transcription-polymerase chain reaction
(RT-PCR). TGF-b1 induced a time-dependent increase in
COX-2 mRNA levels, which peaked at 12 h after addition of
the agonist (Figure 3a). PCR was also performed for the
housekeeping gene glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) mRNA to control for the PCR efficiency and
equal starting amount of total RNA. There was no apparent
change in GAPDH mRNA abundance upon TGF-b1 treat-
ment. As stimulation of HMC resulted in increased
expression of the COX-2 mRNA, we next aimed to assess
changes in COX-2 promoter activity in response to TGF-b1.
HMC were transfected with a luciferase reporter vector
containing an exogenous COX-2 promoter22 and then
stimulated with TGF-b1 (1 ng/ml) for 12 h (Figure 3b).
Our results demonstrated that incubation with TGF-b1
resulted in an increased activity of the COX-2 promoter.
As post-transcriptional regulation of COX-2 expression
includes changes in COX-2 mRNA stability, we examined the
role of a post-transcriptional mechanism involving mRNA
stabilization. To address this possibility, we employed a
classical technique involving the measurement of COX-2
mRNA levels in transcriptionally arrested cells using
actinomycin D (Act D) in the absence or presence of TGF-
b1 (Figure 3c). HMC were treated with TGF-b1 (1 ng/ml) for
12 h (maximum mRNA level; see Figure 3a). At this time
point (0 h), we distinguished three conditions. In the first two
conditions, the medium already containing TGF-b1 was
retained for another 0.5, 1, and 2 h. In the third condition,
the medium was replaced with fresh medium without TGF-
b1. The transcriptional inhibitor Act D (5 mg/ml) was added
to the plates of the second and third conditions. Total RNA
was isolated at the indicated time points and examined for
the presence of COX-2 mRNA by RT-PCR. To correct
differences in loading, the signal density of each COX-2 band
was divided by the signal density of the GAPDH band. As
shown in Figure 3c, we observed that TGF-b1-induced COX-
2 mRNA levels remained relatively stable in non-Act
D-treated samples; however, after Act D halted transcription,
there was a decrease in COX-2 mRNA expression. The
COX-2 mRNA levels dropped in the presence of Act D with
a similar slope in the presence or absence of TGF-b1,
indicating that transcriptional activity, rather than increased
mRNA stability, is the primary mechanism responsible for
TGF-b1-induced increase in COX-2 mRNA levels.
Multiple MAPK routes participate in TGF-b1-induced COX-2
expression in HMC
TGF-b1 is known to induce a number of cellular responses
via ERK1/2 (p44/p42 MAPK).23 Furthermore, activation
of ERK1/2 has been shown to mediate the induction of
COX-2.24,25 Thus, our next objective was to define the role
played by ERK1/2 in TGF-b1-induced COX-2 expression in
HMC. For this purpose, HMC were stimulated with TGF-b1
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Figure 3 | COX-2 expression by TGF-b1 involves transcriptional
mechanisms. (a) HMC were serum-starved (24 h) before stimulation
with TGF-b1 (1 ng/ml). RNA was isolated at the indicated time points
after addition of agonist and COX-2 mRNA was analyzed by RT-PCR.
The expression of GAPDH mRNA was analyzed in the same samples
as a control of the amount of cDNA loaded in each lane. (b) HMC
were transiently cotransfected with 400 ng of the human COX-2
promoter fused to the Luciferase reporter gene and 10 ng of
TK-Renilla plasmid for 5 h in culture medium containing 10% FBS.
Afterwards, cells were deprived of serum for 24 h and treated with
TGF-b1 (1 ng/ml) for 12 h and luciferase and Renilla activities were
determined (*Po0.01). (c) Serum-starved HMC were stimulated with
TGF-b1 (1 ng/ml) in serum-free medium for 12 h. At this time point
(0 h, maximum COX-2 mRNA expression), two sets of HMC were
maintained in the original serum-free medium containing TGF-b1.
One of them was left untreated and the other treated with the
transcriptional inhibitor Act D (5 mg/ml). Fresh serum-free medium
(without TGF-b1) was added to another set of cells treated with Act
D. Total RNA was isolated at each time point, and COX-2 mRNA levels
were analyzed by semiquantitative RT-PCR. Relative levels of COX-2
mRNA expression were determined by densitometric scanning of the
bands and normalized to the GAPDH signal. Values depicted for
mRNA abundance were expressed as a percentage of the control
(0 h). Results are expressed as the mean7s.e.m. of four independent
experiments.
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(1 ng/ml) and ERK1/2 activation was assessed by Western
blot of phospho-ERK. We also studied the effect of inhibiting
the ERK1/2 pathway with the MAP-kinase kinase (MEK)
inhibitors PD98059 and U0126 on TGF-b1-induced COX-2
expression and PGE2 production. TGF-b1 increased ERK1/2
phosphorylation that reached a maximum after 15 min and
then decreased progressively (Figure 4a). Total ERK1/2
remained constant throughout the duration of the experi-
ment. Inhibition of ERK1/2 activation by the MEK inhibitors
PD98059 (50 mM) or U0126 (10 mM) notably decreased the
TGF-b1-dependent COX-2 protein induction in HMC
(Figure 4b). Furthermore, PGE2 production in response to
TGF-b1 was markedly reduced in HMC treated with
PD98059 or U0126 (Figure 4c). We also confirmed the
effectiveness of PD98059 and U0126 in blocking MEK-
dependent activation of ERK1/2 by TGF-b1. As our data
demonstrate, both substances effectively blocked ERK1/2
phosphorylation in basal conditions and after incubation
with TGF-b1 (Figure 4d). Taken together, these results
indicate that the ERK1/2 MAPK pathway participates in
COX-2 increase induced by TGF-b1 in HMC.
TGF-b1 is known to induce a number of cellular responses
via p38 MAPK in several cell types, including MC.26 For this
reason, we have also assessed whether TGF-b1-dependent
COX-2 expression was mediated by activation of p38 MAPK
signalling. For this purpose, serum-starved HMC were
stimulated with TGF-b1 and the level of phosphorylated
p38 MAPK was measured by Western blot. TGF-b1 (1 ng/ml)
promoted a modest but reproducible increase in p38
phosphorylation that reached a maximum after 15 min and
then decreased (Figure 5a). Total p38 remained constant
throughout the duration of the experiment (Figure 5a). To
establish the role that p38 MAPK plays in TGF-b1-dependent
COX-2 expression, HMC were pretreated with the inhibitor
of p38 MAPK activity, SB203580 (10 mM), and then treated
with TGF-b1 for 24 h. We observed that SB203580 reduced
TGF-b1-induced COX-2 protein upregulation (Figure 5b).
Furthermore, the level of TGF-b1-dependent PGE2 produc-
tion was also blocked with SB203580 treatment (Figure 5c).
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Figure 4 | ERK1/2 activation is required for TGF-b1-dependent
COX-2 expression. (a) HMC were serum-starved for 24 h and then
stimulated with TGF-b1 (1 ng/ml) for the indicated time periods. Total
protein extracts were analyzed by Western blotting using specific
antibodies for total and phosphorylated ERK1/2. (b) HMC were
serum-starved for 24 h and pretreated with the MEK1/2 inhibitors
PD98059 (50mM) or U0126 (10 mM) for 30 min before stimulation with
TGF-b1 (1 ng/ml) for 24 h. COX-2 protein expression levels were
analyzed by Western blotting. (c) Cells were serum-starved for 24 h
and pretreated with PD98059 (50 mM) or U0126 (10mM) for 30 min
before stimulation with TGF-b1 (1 ng/ml) for 24 h. Culture medium
was collected and PGE2 was measured by ELISA. PGE2 levels were
corrected by protein amount present in each plate. (d) Serum-starved
HMC were pretreated with PD98059 (50 mM) or U0126 (10 mM) for
30 min before stimulation with TGF-b1 (1 ng/ml) for 15 min. Total
protein extracts were analyzed by Western blotting using specific
antibodies for total and phosphorylated ERK1/2. Errors bars are not
shown where they are smaller than the symbol. Results are expressed
as the mean7s.e.m. of, at least, two independent experiments.
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Figure 5 | TGF-b1-dependent COX-2 expression is mediated by
p38 MAPK. (a) HMC were serum-starved for 24 h and stimulated with
TGF-b1 (1 ng/ml) for the indicated time periods. Total protein extracts
were obtained and analyzed for total and phosphorylated p38 using
specific antibodies. (b) Serum-starved HMC were pretreated with the
p38 MAPK inhibitor SB203580 (10 mM) for 30 min before stimulation
with TGF-b1 (1 ng/ml) for 24 h (for COX-2) or 15 min (for p-HSP27 and
p38). COX-2, p-HSP27, and p38 protein expression levels were
analyzed by Western blotting. (c) Serum-starved HMC were
pretreated with SB203580 (10 mM) for 30 min before stimulation with
TGF-b1 (1 ng/ml) for 24 h. The culture medium was collected to
measure PGE2 by ELISA. PGE2 levels were corrected by protein
amount present in each plate. Results are expressed as the
mean7s.e.m. of, at least, two independent experiments.
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We also assessed the effectiveness of SB203580 in blocking
p38 MAPK activity using an indirect measure of p38 MAPK
activity, the phosphorylation of HSP27.26 HSP27 phosphor-
ylation was stimulated by TGF-b1 treatment for 15 min.
SB203580 blocked TGF-b1-stimulated HSP27 phosphoryla-
tion (Figure 5b). Taken together, these results demonstrate
that the p38 MAPK pathway participates in the COX-2
increase induced by TGF-b1 in HMC.
The PI3K/Akt route participates in the regulation
of TGF-b1-induced COX-2 expression
Several studies have shown the involvement of the phospha-
tidylinositol 3-kinase (PI3K)/Akt pathway in the regulation
of COX-2 expression and PGE2 synthesis.
27,28 As PI3K plays
an important role in TGF-b1-induced collagen expression in
MC,29 our next objective was to assess the role of PI3K in
TGF-b1-induced COX-2 protein expression and PGE2
production in HMC. Our data reveal that TGF-b1 (1 ng/ml)
induced a two-fold increase in Akt phosphorylation after
15 min and returned to basal values by 30 min of incubation
with TGF-b1 (Figure 6a). Total Akt remained constant
throughout the duration of the experiment (Figure 6a). To
determine whether PI3K is involved in TGF-b1-induced
COX-2 expression and PGE2 synthesis in HMC, cells were
incubated with the PI3K inhibitor LY294002. Pretreatment of
HMC with LY294002 (20 mM) considerably attenuated TGF-
b1-induced COX-2 expression (Figure 6b) and PGE2
synthesis (Figure 6c). We also verified the effectiveness of
LY294002 in blocking Akt activation by TGF-b1 in HMC.
Our data reveal that LY294002 (20 mM) completely inhibited
TGF-b1-induced Akt phosphorylation (Figure 6d). These
results suggest that TGF-b1-stimulated COX-2 expression
and PGE2 synthesis are partially mediated through the
activation of the PI3K/Akt pathway in HMC.
TGF-b1-induced proliferation and collagen I synthesis are
independent of COX-2 activation
Our data reveal that TGF-b1 (1 ng/ml) inhibits proliferation
of HMC growing in 10% fetal calf serum after 5 days of
treatment (Figure 7a). The specific COX-2 inhibitor NS-398
also inhibited basal HMC proliferation, thus indicating
that COX-2 induces proliferation of HMC in culture.
To investigate the possible involvement of COX-2 in TGF-
b1-induced inhibition of proliferation, we added NS-398 to
cultured HMC 1 h before the addition of TGF-b1. The
number of cells was the same as in TGF-b1 treatment,
indicating that the TGF-b1-induced proliferation inhibition
is independent of COX-2 activation.
Our data also reveal that TGF-b1 (1 ng/ml) increases
collagen I mRNA and protein expression in HMC (Figure 7c
and d). To study the role of COX-2 in TGF-b1-induced
collagen I expression, we inhibited selectively COX-2 by
adding NS-398 1 h before TGF-b1 treatment. Neither
collagen I mRNA nor protein expression was modified by
inhibition of COX-2 activity, suggesting that TGF-b1-
induced collagen expression is independent of COX-2
activation.
None of the pharmacological inhibitors used – NS-398,
PD98059, U0126, SB203580, and LY294002 – had toxic effect
on the HMC at the concentration used in our cell culture
experiments.
DISCUSSION
In this paper, we describe, for the first time, the effect of TGF-
b1 on COX-2 expression in primary cultured HMC. We show
that TGF-b1 upregulates COX-2 expression and PGE2
production, and identify several signalling routes that are
involved in these actions of TGF-b1.
COX-2 is an inducible enzyme involved in chronic
inflammation.30 Several studies have highlighted an upregu-
lation of COX-2 expression in proliferative glomerulo-
nephritis.31,32 In this study, we demonstrate that TGF-b1
activates COX-2 expression and PGE2 production, whereas
TGF-b1 does not affect COX-1 expression in primary
cultured HMC. This effect is specific for TGF-b1 because
the sTbRII inhibits the effects of TGF-b1 on COX-2
expression and PGE2 production. Furthermore, the PGE2
production in response to TGF-b1 is dependent on
COX-2 activity, as pretreatment with the selective COX-2
inhibitor NS-398 blocked TGF-b1-induced PGE2 production.
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Figure 6 | PI3K/Akt pathway mediates TGF-b1-dependent
COX-2 expression. (a) HMC were serum-starved for 24 h and then
stimulated with TGF-b1 (1 ng/ml) for the indicated time periods. Total
protein extracts were analyzed by Western blotting using specific
antibodies for total and phosphorylated Akt. (b) Serum-starved HMC
were pretreated with the PI3K inhibitor LY294002 (20 mM) for 30 min
before stimulation with TGF-b1 (1 ng/ml) for 24 h. COX-2 protein
expression levels were analyzed by Western blotting. (c) Serum-
starved HMC were pretreated with LY294002 (20 mM) for 30 min
before stimulation with TGF-b1 (1 ng/ml) for 24 h. The culture
medium was collected to measure PGE2 by ELISA. PGE2 levels were
corrected by protein amount present in each plate. (d) Serum-starved
HMC were pretreated with LY294002 (20mM) for 30 min before
stimulation with TGF-b1 (1 ng/ml) for 15 min. Total protein extracts
were analyzed by Western blotting using specific antibodies against
total and phosphorylated Akt. Results are expressed as the
mean7s.e.m. of, at least, two independent experiments.
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Although TGF-b1 is known to induce COX-2 expression in
various cell types,15–17 this is the first time that it has been
demonstrated in HMC.
The regulation of COX-2 expression has been shown to
occur at both transcriptional and post-transcriptional levels.
The stability of COX-2 mRNA is an important regulatory
mechanism of COX-2 expression.33 In the present study, we
demonstrate that administration of TGF-b1 increased the
COX-2 promoter activity and the amount of mRNA for this
gene in HMC. In addition, TGF-b1-induced COX-2 mRNA
expression was inhibited by Act D. All these data suggest that
de novo transcription is required in this process.
It is well recognized that the Smad family of proteins are
key intracellular mediators of TGF-b1 signalling.34 Although
much effort has been made to identify the signalling
pathways triggered by TGF-b1, the signal transduction
mechanisms by which TGF-b1 induces COX-2 protein
expression and PG production are still unclear. Several recent
reports indicate that an important group of protein kinases
may be involved in these processes. This signalling mechan-
ism is believed to control cellular physiological and
pathophysiological processes including cell growth, differ-
entiation, and stress responses.35 Recent work suggests that
the MAPK pathway is also involved in regulating PG
biosynthesis.36–38 Thus, we have assessed the role of MAPK
activation in TGF-b1 induced COX-2 expression and
increased PGE2 synthesis in HMC. In this way, another
major result of this study is that TGF-b1 induces ERK1/2 and
p38 MAPK phosphorylation in a time-dependent manner.
These data are in agreement with those of Chin et al.,39
reporting that TGF-b1 is able to activate the ERK1/2 and the
p38 MAPK, but not JNK, in rat glomerular MC. In addition,
our data demonstrate that pharmacological inhibition of
ERK1/2 and p38 MAPK inhibits TGF-b1-mediated COX-2
upregulation and PGE2 production. Some findings indicate
that SB203580 and PD98059 can directly inhibit thrombox-
ane synthase, and COX-1 and -2, and thus some of the effects
of these inhibitors on PGE2 production could be due to COX
inhibition and alteration in arachidonic acid metabolism.40
However, it should be noted that our results demonstrate that
these inhibitors also decreased the amount of COX-2
detected by Western blot, thus demonstrating that they are
effective in inhibiting COX-2 synthesis. All these data suggest
that in primary cultures of HMC, activation of ERK1/2 and
p38 MAPK mediates TGF-b1-induced COX-2 expression and
increased PGE2 production.
TGF-b1 has been reported to activate or inhibit PI3K
signalling depending on the cell type and the stimulus.41–45
Our results also provide evidence that Akt/PKB activation
plays an important role in TGF-b1-induced expression of
COX-2. The PI3K downstream target Akt is rapidly activated
by TGF-b1 in HMC. Furthermore, we show that inhibition of
PI3K with LY294002 partially blocks TGF-b1-stimulated
COX-2 expression. Similarly, LY294002 reduces the increase
in PGE2 production induced by TGF-b1. Taken together, the
above results suggest that PI3K activation participates in
TGF-b1-mediated full induction of both COX-2 protein
expression and PGE2 production in human renal MC.
TGF-b is an important cytokine in glomerular disease. Its
major role may be to mediate extracellular matrix deposition;
however, TGF-b may also have other important functions in
the glomerulus, including the regulation of cell proliferation,
hypertrophy, and survival, as well as modulation of the local
and systemic immune response. As expected, in our study,
TGF-b induced collagen synthesis and accumulation and
reduced proliferation in HMC. However, neither collagen
type I mRNA, nor net collagen production, nor cell
proliferation was altered by co-treatment with the COX-2
inhibitor NS398. These results suggest that COX-2-derived
prostanoids do not directly interfere with TGF-b1-induced
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Figure 7 | COX-2 mediates proliferation but not collagen
expression induced by TGF-b1 in HMC. (a) HMC were plated in
24-well plates to a density of 4000 per well. The following day, HMC
were stimulated with TGF-b1 (1 ng/ml), the specific COX-2 inhibitor
NS-398 (10 mM), or a combination of both (adding NS-398 1 h before
TGF-b1) in the presence of 10% FBS. Cell proliferation was analyzed at
days 0 (day of treatment) and 5 by an MTT assay. Results are
expressed as number of HMC using a curve correlating number of
HMC and absorbance at 595 nm, and represent the mean7s.e.m. of
three experiments performed in duplicate. (b) At the time, HMC were
plated in 60 mm dishes and treated for 5 days with the previous
agonist. The culture medium was collected and PGE2 concentration
was measured by ELISA. (c) HMC were treated with TGF-b1 (1 ng/ml),
NS-398 (10 mM), or a combination of both (adding NS-398 1 h before
TGF-b1) for 8 h in the presence of 10% FBS. Total RNA was then
isolated and RT-PCR of collagen I (a1) was performed. PGE2
concentration was also measured in the culture medium. (d) HMC
were treated with TGF-b1 (1 ng/ml), NS-398 (10 mM), or a combination
of both for 48 h in the presence of 10% FBS. Total protein extracts
were analyzed by Western blotting using a specific antibody
for collagen I. PGE2 concentration was also measured in the
culture medium.
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inhibition of MC proliferation or extracellular matrix
synthesis ‘in vitro’, although probably could play a role in
glomerular hemodynamics or glomerular inflammation.
In conclusion, our results demonstrate for the first time
that in primary cultures of HMC, TGF-b1 induces the
expression of COX-2 and increases the production of PGE2.
These effects seem to be mediated, at least partially, by the
activation of ERK1/2, p38 MAPK, and PI3K pathways. These
biochemical events may be implicated in normal renal
physiology as well as in the pathogenesis of glomerular
diseases. These results could be useful in elucidating the
molecular mechanisms underlying the regulation of COX-2
in MC and may open up specific strategies for the treatment
of renal glomerular inflammatory diseases that specifically
target the pathways involved in COX-2 activation by TGF-b1.
MATERIALS AND METHODS
Materials
TGF-b1 was from R&D Systems (Minneapolis, MN, USA) and Act
D was from Sigma (Madrid, Spain). NS-398, PD98059, U0126,
SB203580, LY294002, and anti-a-tubulin antibody were from
Calbiochem (Darmstadt, Germany). The sTbRII46 was provided
by Calvin Vary (Center for Molecular Medicine, Maine Medical
Center Research Institute, Scarborough, ME, USA). Antibodies to
COX-1, COX-2, p-ERK1/2, ERK2, Akt, and p38 were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-p-Akt antibody
was from BD Biosciences (Madrid, Spain), anti-collagen I antibody
was from Chemicon (Temecula, CA, USA), and anti-p-p38 and
-p-HSP27 were form Cell Signalling Technology (Beverly, MA, USA).
Cell culture
Primary cultures of HMC were obtained from glomeruli prepared
from the cortex of the intact pole of kidneys removed for
circumscribed tumor, as described previously.47 All kidney tissue
was distant from the neoplasm and macroscopically normal.
Histological examination of these samples revealed no renal
pathology. Cells were maintained in RPMI 1640 medium (Cambrex
Bio Science, Verviers, Belgium) supplemented with 10% fetal bovine
serum (FBS) (GibcoBRL Life Technologies, Paisley, Scotland),
penicillin (50 U/ml), streptomycin (50 mg/ml), sodium selenite
(5 ng/ml), and insulin and transferrin (5 mg/ml each) at 371C in
the presence of 5% CO2. Cells were confirmed as mesangial by
standard morphological and functional criteria.48 Experiments were
performed from passages 4 to 8. Immortalized HMC (clone 18)
were grown in Dulbecco’s modified Eagle’s medium in the presence
of 10% FBS, penicillin (100 U/ml), and streptomycin (100 U/ml) as
described.49
Plasmids, transfection, and luciferase reporter assay
To determine the activity of the COX-2 promoter, 400 ng of the
human COX-2 promoter cloned in the reporter plasmid pXP2 (P2-
1900)22 (a gift from Miguel A In˜iguez, Centro de Biologı´a Molecular
‘Severo Ochoa’, CSIC, Madrid, Spain) and 10 ng of pRL-TK vector
containing the Renilla luciferase gene (Promega, Madison, WI,
USA), used as a control of transfection efficiency, were transiently
cotransfected in immortalized HMC. The day before transfection,
cells were plated into 24-well plates. Cells were transfected in culture
medium containing 10% FBS for 5 h using jetPEI transfection
reagent (Polyplus Transfection, Illkirch, France) according to the
manufacturer’s instructions. Cells were grown in FBS-free medium
for 24 h and treated with TGF-b1 (1 ng/ml) for 12 h. Luciferase and
Renilla activities were measured using a dual-reporter assay kit
(Promega, Madison, WI, USA).
Western blot analyses
Western blot analysis was performed as previously described.50 Cells
were lysed in ice-cold lysis buffer (20 mM Tris-HCl (pH 7.5), 140 mM
NaCl, 10 mM ethylenediaminetetraacetic acid, 10% glycerol, 1%
Nonidet P-40, aprotinin, pepstatin, and leupeptin at 1 mg/ml each,
1 mM phenylmethylsulfonyl fluoride, and 1 mM sodium orthovana-
date). Protein samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis under reducing conditions and
were blotted onto polyvinylidine difluoride membranes. After
incubation with horseradish peroxidase-conjugated secondary anti-
bodies, bands were visualized by a luminol-based detection system
with p-iodophenol enhancement. Anti-a-tubulin antibody was used
to confirm equal loading of protein in each lane. Protein expression
was quantified by densitometry using Scion Image software (Scion,
Frederick, MD, USA).
RT-PCR analyses
Total RNA was isolated using TriReagent (Molecular Research
Center Inc., Cincinnati, OH, USA) and chloroform extraction
according to the manufacturer’s instructions. A 2 mg portion of total
RNA served as template for first-strand cDNA synthesis in a reaction
using oligo(dT) primers and M-MLV reverse transcriptase (Prome-
ga, Madison, WI, USA). A 0.5 mg portion of cDNA was used in a
standard 50 ml PCR mixture with 2 ng/ml of each primer and 2 U of
FastStart Taq DNA polymerase (Roche, Penzberg, Germany). PCR
products were obtained after 35 (for COX-2), 24 (for collagen I
(a1)), or 28 (for GAPDH) cycles of amplification with an annealing
temperature of 581C (for COX-2), 521C (for collagen I (a1)), or
601C (for GAPDH). Primer sequences were as follows: for COX-2,25
forward: 50-TTCAAATGAGATTGTGGGAAAAT-30; reverse: 50-AGA
TCATCTCTGCCTGAGTATCTT-30 (amplifies a fragment of 305 bp);
wfor collagen I (a1), forward: 50-TGTTGCTGAAAGACTACCTCGT-30;
reverse: 50-CCTCCCATGTTAAATAGCACCT-30 (amplifies a fragment
of 303 bp); for GAPDH, forward: 50-TGAAGGTCGGTGTGAACG
GATTTGGC-30; reverse: 50-CATGTAGGCCATGAGGTCCACCAC-30
(amplifies a fragment of 900 bp). PCR products were analyzed by
1% agarose gel electrophoresis containing ethidium bromide and
quantitated digitally using Scion Image software.
PGE2 measurements
HMC plated on 60 mm culture plates were grown in FBS-free
medium for 24 h and treated with TGF-b1 (1 ng/ml) during time
periods referred in each experiment. PGE2 concentration in the
culture medium was measured by enzyme-linked immunosorbent
assay (ELISA) using a PGE2 High Sensitivity Immunoassay kit (R&D
Systems, Minneapolis, MN, USA). PGE2 concentration was
corrected by the protein content in each culture plate. The protein
content was determined by a commercially available variant of the
Lowry method (Bio-Rad, Hercules, CA, USA) using bovine serum
albumin as standard.
Cell proliferation measurements
HMC were plated on 24-well plates to a density of 4000 per well and
allowed to attach overnight. Cells were then treated with 1 ng/ml
TGF-b1, 10 mM NS-398, or a combination of both in the presence
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of 10% FBS. Cell proliferation was analyzed at days 0 and 5 of
treatment by a 3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium
bromide-based assay (Roche) as per the manufacturer’s recommen-
dations. The absorbance of the samples was then measured at
595 nm, and the results transformed in cell number with a curve that
correlated absorbance and number of HMC.
Cytotoxicity assay
HMC were treated with and without pharmacological inhibitors:
10 mM NS-398, 50 mM PD98059, 10 mM U0126, 10 mM SB203580, and
20 mM LY 294002 and cytotoxicity was assessed by the Toxilight
BioAssay Kit (Cambrex, Verviers, Belgium), a commercial kit that
quantitatively measures the release of adenylate kinase from
damaged cells.
Statistical analysis
All the values are presented as the mean showing the s.e.m.
Statistical analysis for luciferase reporter assay was performed
with the Student’s t-test using SPSS 12.0 software (SPSS, Chicago,
IL, USA).
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